A Phase 3, Multicenter, Four-week, Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy And Safety Trial Of Flexible Doses Of Oral Ziprasidone In Children And Adolescents With Bipolar I Disorder (Current Or Most Recent Episode Manic)

Trial Profile

A Phase 3, Multicenter, Four-week, Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy And Safety Trial Of Flexible Doses Of Oral Ziprasidone In Children And Adolescents With Bipolar I Disorder (Current Or Most Recent Episode Manic)

Recruiting
Phase of Trial: Phase III

Latest Information Update: 09 Aug 2017

At a glance

  • Drugs Ziprasidone (Primary)
  • Indications Bipolar I disorders
  • Focus Registrational; Therapeutic Use
  • Sponsors Pfizer
  • Most Recent Events

    • 03 Aug 2017 Planned End Date changed from 31 Jan 2018 to 1 Oct 2021.
    • 03 Aug 2017 Planned primary completion date changed from 25 Jan 2018 to 1 Oct 2021.
    • 06 Mar 2017 Planned End Date changed from 1 Jan 2018 to 31 Jan 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top